Use of Intravenous Paracetamol in Combination with Morphine in sickle cell disease children with vaso-occlusive crisis
ISRCTN | ISRCTN34491330 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN34491330 |
Secondary identifying numbers | 310 |
- Submission date
- 28/09/2009
- Registration date
- 26/10/2009
- Last edited
- 26/10/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Haematological Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Yasser Wali
Scientific
Scientific
AL-Khoud
Sultanate of Oman
Muscat
123
Oman
yasser_wali@hotmail.com |
Study information
Study design | Single-blinded randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Efficacy of intravenous paracetamol in combination with opiod infusion for sickle cell disease children in vaso-occlusive crisis: a single-blinded randomised trial |
Study acronym | IPCM |
Study objectives | To look for any reduction in the amount of morphine and duration of hospitalisation as a result of using intravenous (IV) paracetamol. |
Ethics approval(s) | Approved by the Medical Research and Ethics Committee of Sultan Qaboos University, Oman (ref: 310) |
Health condition(s) or problem(s) studied | Sickle cell disease with vaso-occlusive crisis |
Intervention | Use of IV paracetamol in combination with morphine versus use of placebo with morphine: Group A (standard treatment): morphine (weight of the child multiplied by constant 0.5 = *mg of morphine) and placebo (50 ml of starch/dextromaltose, one hour duration, six hourly) Group B (intervention treatment): morphine infusion and intravenous paracetamol infusion. Morphine dose is calculated as in group A, and dose of paracetamol will be 15 mg/kg/dose every six hourly in a one hour infusion. Duration of treatment depends on the response of the pain; no standard period. The period of hospital stay will be compared later to see if there is any reduction by adding IV paracetamol to morphine treatment. The patient will have liver function tests performed at the beginning of the treatment to establish a baseline, and then the patient will be followed up in the out-patient clinic. *mg of morphine is added to 50 ml 5% dextrose. 1 ml/hr is equal to 10 µg/kg/hr. The starting rate is 5 ml/hr which is equal to 50 µg/kg/hr. The rate is titrated according to the response of pain. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Morphine, intravenous (IV) paracetamol |
Primary outcome measure | Reduction in the amount of morphine and duration of hospitalisation, assessed on a daily basis. |
Secondary outcome measures | Assessed on a daily basis: 1. Reduction in duration of hospital stay (days) for pain relief 2. Reduction in pain severity on a scale of 1 - 10, which will be assessed each shift 3. Reduction of morphine requirements 4. Reduction in morphine side effects namely: prurities, nausea/vomiting, urinary retention |
Overall study start date | 01/05/2008 |
Completion date | 01/05/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Child |
Lower age limit | 2 Years |
Upper age limit | 13 Years |
Sex | Both |
Target number of participants | 200 |
Key inclusion criteria | All sickle cell disease (SCD) children (aged 2 - 13 years, either sex) admitted with vaso-occlusive crisis (VOC) in B2 (blue two) ward of Sultan Qaboos University Hospital (SQUH) |
Key exclusion criteria | 1. Children aged less than one year 2. Children with fever of more than 38.5°C 3. Children with prior side effects of morphine 4. Children with prior history of side effects of paracetamol 5. Children with severe jaundice or severe liver impairment |
Date of first enrolment | 01/05/2008 |
Date of final enrolment | 01/05/2010 |
Locations
Countries of recruitment
- Oman
Study participating centre
AL-Khoud
Muscat
123
Oman
123
Oman
Sponsor information
Sultan Qaboos University (Oman) - College of Medicine and Health Sciences
University/education
University/education
AL-Khoud
Sultanate of Oman
Muscat
123
Oman
Website | http://www.squ.edu.om/ |
---|---|
https://ror.org/049xx5c95 |
Funders
Funder type
University/education
Sultan Qaboos University (Oman) - College of Medicine and Health Sciences
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |